Mesoblast (ASX:MSB) Receives 7-Year FDA Orphan Drug Approval for Ryoncil™
Mesoblast (ASX:MSB) secures 7-year FDA orphan-drug exclusivity for Ryoncil™ in treating pediatric SR-aGvHD, strengthening its IP protection.
Category: ASX-MSB
Mesoblast
Mesoblast Limited (ASX:MSB) Announces Q3 2025 Highlights
Mesoblast Limited (ASX:MSB) reports Q1 2025 milestones, including the US launch of Ryoncil® and strong financial performance.
Mesoblast (ASX:MSB) Announces U.S. Tariff Exemption for Allogeneic Cell Therapies
Mesoblast (ASX:MSB) announces its allogeneic cell therapies are exempt from U.S. tariffs as ‘U.S. Country of Origin’ products.
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil®
Mesoblast (ASX:MSB) enters Medicaid agreement with CMS for Ryoncil®, enabling treatment for children with SR-aGvHD.